Propensity score adjustment with multilevel data: Setting your sites on decreasing selection bias

Annals of Internal Medicine

Volumn 152, Issue 6, 2010, Pages 393-396

  Griswold, Michael E ^a   Russell Localio, A ^b   Mulrow, Cynthia ^c  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Annals of Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; OMEPRAZOLE; PROTON PUMP INHIBITOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK BENEFIT ANALYSIS; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; EPIDEMIOLOGY; NOTE; STATISTICAL ANALYSIS;

CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY, COMBINATION; GASTROINTESTINAL HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; SELECTION BIAS; TICLOPIDINE;

EID: 77950912887     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-6-201003160-00010     Document Type: Editorial

References (10)

1. Ray WA, Murray KT, Griffin MR, Chung CP, Smalley WE, Hall K, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. A cohort study. Ann Intern Med. 2010;152:337-45.
2. U.S. Food and Drug Administration. FDA announces new warning on Plavix: avoid use with Prilosec/Prilosec OTC [news release]. 18 November 2009. Silver Spring, MD: U.S. Food and Drug Administration; 2009. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm191169.htm 8 February 2010.
3. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores [Editorial]. Ann Intern Med. 2002;137:693-5. [PMID: 12379071]
4. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17: 2265-81. [PMID: 9802183]
5. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006; 25:2084-106. [PMID: 16220490]
6. Heagerty PJ, Zeger SL. Marginalized multilevel models and likelihood inference. Stat Sci. 2000;15:1-26.
7. Kang JDY, Schafer JL. Demystifying double robustness: a comparison of alternative strategies for estimating a population mean from incomplete data. Stat Sci. 2007;22:523-39.
8. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-8. [PMID: 19176635]
9. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-44. [PMID: 19258584]
10. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374:989-97. [PMID: 19726078]